NL-OMON42272已完成不适用
A multi-centre, open-label, follow-on study to assess long-term safety and tolerability of intracerebroventricular administration of sNN0029 in patients with amyotrophic lateral sclerosis - Follow on study of sNN0029 with ALS patients.
ewron Sweden AB0 个研究点目标入组 9 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 9
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Previous participation in sNN0029-003 with completion of 12 weeks treatment without clinically significant safety concerns
- •2. Intact continuity of the Medtronic SynchroMed® II Infusion System as judged by X-ray of head and abdominal area
- •3. Clinical diagnosis of ALS classified as definite, or probable with or without additional laboratory evidence, according to the revised WFN El Escorial criteria
- •4. Patient has been given written and verbal information about the continuation study, has had the opportunity to ask questions about the study, and understands the time and procedural commitments
- •5. Patient has given oral and / or signed consent (written) to participate in the study. In the event that a patient who gives oral informed consent is not physically able to sign the informed consent form (ICF) due to disease progression, a witness may sign the informed consent form on the patient*s behalf
排除标准
- •1. Hypertension defined as blood pressure >160 mmHg systolic or >90 mmHg diastolic
- •2. Ophthalmological examination (fundus photography, visual acuity and perimetry) with any clinically significant findings that imply safety concerns for this study.
- •3. Diagnosis of diabetes mellitus
- •4. Presence of risk for increased or uncontrolled bleeding and/or risk of bleeding that cannot be not managed optimally due to:
- •a. anatomical factors at or near the implant site (e.g., vascular abnormalities, neoplasms, or other abnormalities)
- •b. underlying disorders of the coagulation cascade, platelet function, or platelet count (e.g., haemophilia, Von Willebrand*s disease, liver disease, or other medical conditions)
- •5. Presence of additional risk factors for thromboembolism such as obesity (Body mass index [BMI] > 35) or use of oestrogens including combined contraceptive pills
- •6. Clinically significant abnormalities in haematology or clinical chemistry parameters as assessed by the investigator
- •7. Ongoing medical condition that according to the investigator would interfere with the conduct and assessments in the study. Examples are medical disability (e.g., severe degenerative arthritis, compromised nutritional state, peripheral neuropathy) that would interfere with the assessment of safety and efficacy of investigational product or device performance, or would compromise the ability of the patient to undergo study procedures (e.g., MRI), or to give informed consent
- •8. For women only: pregnant, breast feeding and/or for fecund women unwillingness to use adequate contraception during the trial such as:
- •a. Established use of oral, injected or implanted hormonal methods of contraception that do NOT contain oestrogens
- •b. Placement of an intrauterine device
- •c. Barrier methods of contraception: Condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository
研究者
相似试验
进行中（未招募）
不适用
A Multi-Centre, Open Label, Follow-on Study to Assess the Maintenance of Effect, Tolerance and Safety of Sativex in the Treatment of Subjects with Neuropathic PaiEUCTR2004-004395-36-BEGW Pharma Ltd416
进行中（未招募）
1 期
A Multi-Centre, Open Label, Follow-on Study to Assess the Maintenance of Effect, Tolerance and Safety of Sativex in the Treatment of Subjects with Neuropathic Pain. This will be followed by a randomised withdrawal phase (Part B) for a subset of patients.EUCTR2004-004395-36-CZGW Pharma Ltd383
进行中（未招募）
不适用
An open-label, multi-center, follow-up study designed to evaluate the long-term effects of rasagiline in Parkinson?s disease subjects who participated in the ADAGIO study - ADAGIO Follow -UpParkinson?s diseaseMedDRA version: 12.0Level: LLTClassification code 10013113Term: Disease Parkinson'sEUCTR2009-011541-24-ITTeva Pharmaceutical Industries Ltd700
进行中（未招募）
不适用
Effectiveness and safety of BGG492 as add-on treatment in patients with partial onset seizuresEpilepsy Partial onset seizuresMedDRA version: 13.1Level: PTClassification code 10061334Term: Partial seizuresSystem Organ Class: 10029205 - Nervous system disordersEUCTR2010-021448-17-DEovartis Pharma Services AG62
进行中（未招募）
不适用
A multicenter, open-label, follow-up study to evaluate the long-term safety and tolerability of BGG492 TID as adjunctive therapy in patients with partial onset seizures completing double-blind, placebo-controlled study CBGG492A2207 or CBGG492A2211. - not availableEpilepsy Partial onset seizuresMedDRA version: 12.1Level: LLTClassification code 10065336Term: Partial epilepsyEUCTR2010-021448-17-HUovartis Pharma Services AG